Childhood Hematopoietic Cell Transplantation–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (01/27/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Allogeneic Hematopoietic Cell Transplantation (HCT)

Added Improved Outcomes After Allogeneic Transplantation as a new subsection.

Added Haines et al. as reference 97.

Complications After HCT

Added text to state that pediatric patients who have severe veno-occlusive disease without increased bilirubin have been reported; therefore, it is important to be vigilant about monitoring patients who have other symptoms without increased bilirubin (cited Myers et al. as reference 20).

Added text about a study that reviewed causes of late mortality after second allogeneic transplantation (cited Duncan et al. as reference 69).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Current Clinical Trials

Next section >
About This PDQ Summary